+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 68 Pages
  • June 2024
  • GlobalData
  • Grifols, S.A.
  • ID: 1292070
Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Grifols SA (Grifols) develops, produces, and markets plasma-derived medicines and transfusion medicines. The company is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. The company's major products include essential plasma-derived medicines for treating conditions across various therapeutic areas such as neurology, immunology, hepatology, intensive care, pulmonology, hematology, and infectious diseases. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.

Grifols SA Key Recent Developments

  • Apr 30, 2024: Grifols Successfully Completes Its Eur 1 Billion Private Placement of Senior Secured Notes
  • Apr 23, 2024: Grifols Announces Signing of Private Offering of EUR 1 Billion Senior Secured Notes Due 2030
  • Apr 19, 2024: Grifols 2023 Annual Report on Form 20-F filed with the SEC
  • Apr 02, 2024: Nacho Abia begins tenure as new Grifols CEO

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Grifols SA - Key Facts
  • Grifols SA - Key Employees
  • Grifols SA - Key Employee Biographies
  • Grifols SA - Major Products and Services
  • Grifols SA - History
  • Grifols SA - Company Statement
  • Grifols SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Grifols SA - Business Description
  • Business Segment: Bio Supplies
  • Overview
  • Performance
  • Business Segment: Biopharma
  • Overview
  • Performance
  • Business Segment: Diagnostic
  • Overview
  • Performance
  • Business Segment: Others
  • Overview
  • Performance
  • Geographical Segment: European Union
  • Target Markets
  • Performance
  • Geographical Segment: Rest of the World
  • Performance
  • Geographical Segment: Spain
  • Performance
  • Geographical Segment: USA and Canada
  • Performance
  • R&D Overview
  • Grifols SA - Corporate Strategy
  • Grifols SA - SWOT Analysis
  • SWOT Analysis - Overview
  • Grifols SA - Strengths
  • Grifols SA - Weaknesses
  • Grifols SA - Opportunities
  • Grifols SA - Threats
  • Grifols SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Grifols SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 30, 2024: Grifols Successfully Completes Its Eur 1 Billion Private Placement of Senior Secured Notes
  • Apr 23, 2024: Grifols Announces Signing of Private Offering of EUR 1 Billion Senior Secured Notes Due 2030
  • Apr 19, 2024: Grifols 2023 Annual Report on Form 20-F filed with the SEC
  • Apr 02, 2024: Nacho Abia begins tenure as new Grifols CEO
  • Feb 29, 2024: Grifols Closes a Record Year and Accelerates Profitable Growth for 2024
  • Feb 05, 2024: Grifols Announces Changes in Governance to Separate Management From Ownership as Part of Planned Strategy
  • Feb 01, 2024: Grifols Names New Senior Executives
  • Dec 19, 2023: Victor Grifols Roura Announces Retirement from Grifols Board of Directors; Albert Grifols ComaCros assumes the vacated seat
  • Dec 04, 2023: Grifols Accelerates EBITDA Margin Expansion to 25.1% And Further Improves Its Operating Performance
  • Nov 16, 2023: Grifols Launches New Solution to Facilitate Pre-transfusion Compatibility Testing in Multiple Myeloma Patients
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Grifols SA, Key Facts
  • Grifols SA, Key Employees
  • Grifols SA, Key Employee Biographies
  • Grifols SA, Major Products and Services
  • Grifols SA, History
  • Grifols SA, Other Locations
  • Grifols SA, Subsidiaries
  • Grifols SA, Key Competitors
  • Grifols SA, Ratios based on current share price
  • Grifols SA, Annual Ratios
  • Grifols SA, Interim Ratios
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Grifols SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Grifols SA, Performance Chart (2019 - 2023)
  • Grifols SA, Ratio Charts
  • Grifols SA, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Grifols SA, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Vertex Pharmaceuticals Inc
  • Oryzon Genomics SA
  • Korro Bio Inc
  • Kamada Pharmaceuticals
  • Abeona Therapeutics Inc
  • AATec Medical GmbH
  • Mereo Biopharma Group Plc
  • AB-Biotics SA
  • Takeda Pharmaceutical Co Ltd
  • Kedrion Biopharma Inc
  • Bio Products Laboratory Ltd
  • Sanofi
  • Octapharma Plasma Inc
  • HemaCare Corp
  • Omnicell Inc
  • CSL Behring GmbH